![Samuel Reed](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samuel Reed
Chief Executive Officer at DNAe Group Holdings Ltd.
Samuel Reed active positions
Companies | Position | Start | End |
---|---|---|---|
DNAe Group Holdings Ltd.
![]() DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Career history of Samuel Reed
Statistics
International
United Kingdom | 2 |
Operational
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
DNAe Group Holdings Ltd.
![]() DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Health Technology |
- Stock Market
- Insiders
- Samuel Reed
- Experience